Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

864 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.
Tai YK, Chan KKW, Fong CHH, Ramanan S, Yap JLY, Yin JN, Yip YS, Tan WR, Koh APF, Tan NS, Chan CW, Huang RYJ, Li JZ, Fröhlich J, Franco-Obregón A. Tai YK, et al. Among authors: chan cw, chan kkw. Front Oncol. 2022 Jan 24;11:783803. doi: 10.3389/fonc.2021.783803. eCollection 2021. Front Oncol. 2022. PMID: 35141145 Free PMC article.
Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.
Tai YK, Chan KKW, Fong CHH, Ramanan S, Yap JLY, Yin JN, Yip YS, Tan WR, Koh APF, Tan NS, Chan CW, Huang RYJ, Li JZ, Fröhlich J, Franco-Obregón A. Tai YK, et al. Among authors: chan cw, chan kkw. Front Oncol. 2022 Apr 20;12:892408. doi: 10.3389/fonc.2022.892408. eCollection 2022. Front Oncol. 2022. PMID: 35515135 Free PMC article.
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, Chan CW, Hartman M, Lim SE, Ngoi N, Tang SW, Ang Y, Chan G, Chong WQ, Tan HL, Tan SH, Goh BC, Lee SC. Yadav K, et al. Among authors: chan cw, chan g. Breast Cancer Res Treat. 2022 Feb;192(1):131-142. doi: 10.1007/s10549-021-06470-7. Epub 2021 Dec 20. Breast Cancer Res Treat. 2022. PMID: 34928481 Free PMC article. Clinical Trial.
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.
Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh TI, Pang AS, Tan CS, Ow SG, Wang L, Mogro J, Ho J, Jeyasekharan AD, Huang Y, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA, Goh BC, Lee SC. Wong AL, et al. Among authors: chan cw. Oncotarget. 2016 Sep 27;7(39):64089-64099. doi: 10.18632/oncotarget.11596. Oncotarget. 2016. PMID: 27577069 Free PMC article. Clinical Trial.
Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL, Yuan Y, Lai X, Tan TZ, Wang L, Huang BB, Pandey V, Huang RY, Lobie PE, Goh BC, Sethi G, Yap CT, Chan CW, Lee SC, Kumar AP. Ang HL, et al. Among authors: chan cw. Theranostics. 2021 Jan 1;11(3):1115-1128. doi: 10.7150/thno.49716. eCollection 2021. Theranostics. 2021. PMID: 33391524 Free PMC article. Review.
DNA methylation and breast cancer-associated variants.
Ho PJ, Dorajoo R, Ivanković I, Ong SS, Khng AJ, Tan BK, Tan VKM, Lim SH, Tan EY, Tan SM, Tan QT, Yan Z, Ngeow J, Sim Y, Chan P, Chuan JCJ, Chan CW, Tang SW, Hartman M, Li J. Ho PJ, et al. Among authors: chan p, chan cw. Breast Cancer Res Treat. 2021 Aug;188(3):713-727. doi: 10.1007/s10549-021-06185-9. Epub 2021 Mar 26. Breast Cancer Res Treat. 2021. PMID: 33768416
864 results